TerSera Therapeutics - About the company
TerSera Therapeutics is a series A company based in Lake Forest (United States), founded in 2008. It operates as a Developer and manufacturer of medicines for various therapeutic areas. TerSera Therapeutics has raised $2.68M in funding from CoSci Med-Tech. The company has 2090 active competitors, including 114 funded and 219 that have exited. Its top competitors include companies like AbbVie, Merck and Gilead.
Company Details
TerSera Therapeutics is focused on acquiring and developing pharmaceutical products. The therapeutic areas the company is looking at include allergy/immunology, CNS disorders, endocrinology, gastroenterology, infectious disease, oncology, orphan diseases, rheumatology, transplant-related therapies, urology, and women’s health.
- Website
- tersera.com
- Email ID
- *****@tersera.com
- Phone Number
- +1 **********
- Registered Address
- Deerfield, Illinois
Key Metrics
Founded Year
2008
Location
Lake Forest, United States
Stage
Series A
Total Funding
$2.68M in 6 rounds
Latest Funding Round
Investors
Ranked
46th among 2090 active competitors
Employee Count
214 as on Sep 30, 2026
Investment & Acquisitions
Legal entities associated with TerSera Therapeutics
TerSera Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Tersera Therapeutics Llc CIN: 811458652 , United States, Active | Dec 26, 999 | - | 160 (As on Dec 31, 2024) | - |
Sign up to download TerSera Therapeutics' company profile
TerSera Therapeutics's funding and investors
TerSera Therapeutics has raised a total funding of $2.68M over 6 rounds. Its first funding round was on Oct 01, 2010. Its latest funding round was a Series A round on Jun 21, 2016 for $*****. 1 investor participated in its latest round. TerSera Therapeutics has 3 institutional investors.
Here is the list of recent funding rounds of TerSera Therapeutics:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 21, 2016 | 9065264 | Series A | 2559701 | 3901307 | 4923316 | 5610501 |
Feb 04, 2016 | 8576182 | Seed | 7914803 | 1984651 | 4972845 | |
Mar 12, 2013 | 9023123 | Seed | 4031168 | 8216516 | 4751476 | 6857649 |
View details of TerSera Therapeutics's funding rounds and investors
TerSera Therapeutics' founders and board of directors
Founder? Claim ProfileTerSera Therapeutics' employee count trend
TerSera Therapeutics has 214 employees as of Sep 26. Here is TerSera Therapeutics's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
TerSera Therapeutics's Competitors and alternates
Top competitors of TerSera Therapeutics include AbbVie, Merck and Gilead. Here is the list of Top 10 competitors of TerSera Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 84/100 | |
2nd | Merck 1891, Rahway (United States), Public | Manufacturer of pharmaceutical products | - | 83/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 82/100 | |
4th | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 80/100 | |
5th | AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 77/100 | |
6th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 76/100 | |
7th | Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 72/100 | |
9th | Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 71/100 | |
10th | Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 71/100 | |
46th | TerSera Therapeutics 2008, Lake Forest (United States), Series A | Developer and manufacturer of medicines for various therapeutic areas | $2.68M | 61/100 |
Looking for more details on TerSera Therapeutics's competitors? Click here to see the top ones
TerSera Therapeutics's Investments and acquisitions
TerSera Therapeutics has acquired TerSera. TerSera Therapeutics has not made any investments as of now.Reports related to TerSera Therapeutics
Here is the latest report on TerSera Therapeutics's sector:
News related to TerSera Therapeutics
Media has covered TerSera Therapeutics for a total of 2 events in the last 1 year.
•
ESTEVE acquires Infusion Specialty Therapies business from TerSera Therapeutics, expanding its presence in the USAPR Newswire•Jan 13, 2026•Esteve, TerSera Therapeutics
•
JLL to provide leasing, property management services at Deerfield’s Corporate 500 office campushttps://www.rejournals.com•Sep 17, 2025•TerSera Therapeutics, JLL
•
TerSera Therapeutics to Present Data on PRIALT® at ASPN 2025Business Wire•Jul 18, 2025•TerSera Therapeutics
•
TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumBusiness Wire•Dec 12, 2024•TerSera Therapeutics
•
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®Business Wire•Oct 22, 2024•TerSera Therapeutics, MacroGenics
•
TerSera Therapeutics to acquire global rights to MARGENZASeeking Alpha•Oct 22, 2024•TerSera Therapeutics, MacroGenics
•
•
TerSera’s ZOLADEX LA gains Health Canada approval for breast cancerPharmaceutical Technology•May 08, 2024•TerSera Therapeutics
•
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations OfficerGlobeNewswire•Dec 21, 2020•MG Motor India, TerSera Therapeutics
•
GTCR-backed TerSera Therapeutics agrees to buy the Xermelo product from Lexicon PharmaceuticalsPE Hub•Aug 03, 2020•TerSera Therapeutics, Lexicon Pharmaceuticals
Are you a Founder ?
FAQs about TerSera Therapeutics
Explore our recently published companies
- PerMED AI - Unfunded company
- PERLeman - Saint-sulpice based, 2024 founded, Unfunded company
- Peritio AI - Unfunded company
- Perkins Civil - Magnolia based, 2025 founded, Unfunded company
- PeritaBot AI - Unfunded company
- Peristyle AI - 2026 founded, Unfunded company
